News Shire tipped as next big pharma takeover target After trial failure, shares rallied on takeover rumours
News Shire's Hunter Syndrome cognitive impairment drug fails Trial missed primary and secondary endpoints
News Shire CEO backs outcomes-based deals in rare diseases Strategy could help make rare disease drugs affordable
News Judge throws out Allergan patents, criticises Native America... Federal court throws out patents on Restasis
News Intercept shares dive after FDA safety alert on liver drug Regulator warns of death risk in patients on higher than recommended dose.
Partner Content Partner Content 5 Key Reasons Why You Should Attend Europe's Leading Ophthal... 5 Key Reasons Why You Should Attend
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.